GlassScriptPhysician profile
Douglas A Henning
NPI 1316017155
$538.19
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $24.52 · 2022: $120.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $119.64 | 2022 | |
| Shire North American Group INC | $102.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.52 | 2019 | |
| Amarin Pharma, INC. | $42.46 | 2019-2020 | |
| Alk-Abello, INC | $32.60 | 2019 | |
| Glaxosmithkline, LLC. | $31.46 | 2019 | |
| Optinose US, INC. | $26.37 | 2019 | |
| Philips North America LLC | $24.36 | 2019 | |
| Genzyme Corporation | $15.53 | 2019 | |
| Csl Behring | $14.69 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.35 | 2019 | |
| Cranial Technologies, INC | $13.83 | 2019 | |
| Abbott Laboratories | $13.26 | 2019 | |
| Kaleo, INC. | $13.15 | 2019 | |
| Genentech USA, INC. | $11.40 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11.34 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Henning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.